{"entity":{"id":"nct05609968","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","aka":["EVOKE-03"],"tldr":"A phase 3 trial of Sacituzumab govitecan and Pembrolizumab in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46). ClinicalTrials.gov record last updated 2025-12-24: active not recruiting. Enrollment is planned at 614 participants. Primary completion is estimated at 2027-01-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab Govitecan, Pembrolizumab. Registered primary measures: Progression-Free Survival (PFS); Overall Survival (OS).","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05609968","url":"https://clinicaltrials.gov/study/NCT05609968"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","pdl1-high-nsclc"],"sections":[],"technologies":["adc","checkpoint-inhibitor","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["sacituzumab-govitecan","pembrolizumab"],"companies":["merck","gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2025-12-24: active not recruiting. Enrollment is planned at 614 participants. Primary completion is estimated at 2027-01-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT05609968","phase":"3","setting":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT05609968","source":"https://clinicaltrials.gov/study/NCT05609968","fetchedAt":"2026-10-07T16:53:47.239Z","studySha256":"b6bec6d011701430702149d9ed33ad1694cb01fd46fba9c0f7f4e209f9470adb","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-12-24","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":614,"enrolmentType":"ESTIMATED","siteCount":180,"recruitingSiteCount":0,"countries":["Australia","Brazil","Canada","Chile","China","Estonia","Germany","Greece","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Peru","Philippines","Poland","Romania","South Korea","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-02-06","startedType":"actual","enrolled":614,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05609968/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}